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Abstract
Background: People with multiple sclerosis have high risk of osteoporosis and fractures. A poor vitamin D status is
a risk factor for MS, and vitamin D supplementation has been recommended both to prevent MS progression and
to maintain bone health.
Methods: We assessed the effect of 20,000 IU vitamin D3 weekly compared to placebo on biochemical markers of
bone metabolism in 68 persons with relapsing remitting multiple sclerosis.
Results: Serum levels of 25-hydroxyvitamin D more than doubled in the vitamin D group, and parathyroid hormone
decreased in the vitamin D group compared to the placebo group at week 48 and week 96. There was however no
effect on bone formation as measured by procollagen type I N propeptide (PINP), or on bone resorption as measured
by C-terminal cross-linking telopeptide of type I collagen (CTX1). Neither PINP nor CTX1 predicted bone loss from
baseline to week 96.
Conclusions: These findings corroborate the previously reported lack of effect of weekly high dose vitamin D
supplementation on bone mass density in the same patients, and suggest that such vitamin D supplementation
does not prevent bone loss in persons with MS who are not vitamin D deficient.
Trial registration: The trial was registered at ClinicalTrials.gov on April 4 2008, registration number NCT00785473.
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Background
Low levels of vitamin D are associated with increased fu-
ture risk of developing multiple sclerosis and with in-
creased disease activity [1–3]. Vitamin D is also essential
for bone health. Several studies have shown that people
with multiple sclerosis (MS) are at increased risk of de-
veloping osteoporosis [4, 5]. Physical disability is likely
the main driver of accelerated bone loss in MS, but also
disease duration and lifetime steroid dose are associated
with low bone mineral density (BMD) [4, 6]. Low BMD
is however prevalent also in ambulatory persons with
MS even shortly after clinical onset [6, 7], suggesting
that shared etiological factors such as low vitamin D
may operate in both MS and osteoporosis.
The combination of osteoporosis and high risk of falling
may add to the burden of disease through increased risk of
fractures. In line with this, large population based studies
have shown that persons with MS have a marked increase
of fractures compared to the general population [8–12].
Data from the Danish MS Registry and The National Hos-
pital Discharge Registry showed that the risk of fractures of
tibia, hip and femur in persons with MS was three to six
times higher than in the general population [10].
Although the role of vitamin D supplementation on
disease activity in MS is unclear [13], several authors
have suggested that vitamin D should be monitored to
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prevent osteoporosis and fractures [5, 14–16]. The optimal
intake of vitamin D and serum level of 25-hydroxyvitamin
D is however controversial. Whereas the National Institute
of Medicine considers a serum level of 25-hydroxyvitamin
(25(OH)D) at 50 nmol/L and a daily intake of 600 IU vita-
min D adequate for the general population [17], others
argue that the serum level needed for both optimal bone
health and for the potentially beneficial non-calcemic ef-
fects is at least 75 nmol/L [18–20]. There is, however lim-
ited evidence on the effect of vitamin D supplementation
on bone heath in MS.
We have previously reported a randomized controlled
trial (RCT) of weekly supplementation with 20,000 IU
vitamin D3 compared to placebo in fully ambulatory
(expanded disability status scale ≤4.5) persons with re-
lapsing remitting MS living above the Arctic Circle
[21]. This dose has proven safe in several RTCs in the
same area [22]. Even though people with MS may need
more vitamin D than others to reach the same 25-
hydroxyvitamin D (25(OH)D) serum concentration, [23],
we expected that this dose would bring the vast majority
of patients to 25(OH)D levels considered optimal for bone
health and also within the range associated with de-
creased disease activity. Although bone mineral dens-
ity (BMD) decreased significantly in the placebo group
and not in the vitamin D treated group, the primary out-
come (difference in percentage change in BMD between
groups) was negative [21].
The markers of bone formation procollagen type I N
propeptide (PINP) and bone resorption C-terminal
cross-linking telopeptide of type I collagen (CTX1) have
been shown to predict fracture risk and to reflect the re-
sponse to osteoporosis treatment [24]. These markers
are recommended as reference markers in observational
and treatment studies in osteoporosis by the International
Osteoporosis Foundation and the International Federation
of Clinical Chemistry and Laboratory Medicine [25], and
could be more sensitive for treatment effects than BMD.
The aim of the current study was to examine if CTX and
PINP predict bone loss, and if vitamin D3 supplementa-
tion affect these markers of bone formation and turnover
in persons with MS.
Methods
The design of the RCT have been reported previously
[21, 26]. Briefly, 71 RRMS patients from Troms and
Finnmark (the northernmost counties in Norway), aged
18–50 years and with Kurtzke’s Expanded Disability Status
Scale (EDSS) score ⩽4.5 were included in the original
study [21]. The exclusion criteria comprised a history of
conditions or diseases affecting bone, pregnancy or lacta-
tion the past 6 months, use of bone-active medications
other than intravenous methylprednisolone for treatment
of MS relapses, a history of nephrolithiasis during the pre-
vious 5 years, or menopause.
The participants were randomized to receive either
once-weekly oral 20,000 IU vitamin D3 (Dekristol™;
SWISS CAPS AG, Kirchberg, Switzerland) or placebo.
All participants also received 500 mg calcium daily (cal-
cium carbonate, Weifa AS, Oslo, Norway). Participants
who had gastrointestinal side effects attributed to Weifa
calcium switched to Calcium Sandoz™ effervescent tablets
(calcium lactate-gluconate and calcium carbonate, Sandoz
A/S, Odense, Denmark), or discontinued the calcium sup-
plement if their estimated dietary calcium intake as
measured by a validated food frequency questionnaire
exceeded 800 mg/day [27]. By capsule count, all sub-
jects were ≥80% (mean 98%, range 80–100%) adherent
to the study medication [21].
Measurement of BMD at the hip (mean of left and
right), the spine (anterior–posterior spine L1–L4), and
the non-dominant ultra-distal radius by DXA (dual X-ray
absorptiometry) was performed by trained technicians at
the University Hospital of North-Norway, using a Lunar
Prodigy advanced densitometer (Lunar Radiation Corp.,
Madison, WI, USA.). The long-term precision was 0.26–
0.28%, obtained by daily calibration of the densitometer.
One fourth of the patients had low BMD (z-scores
blow −2) at baseline [6].
Serum samples were collected at baseline (January or
February for all participants) and at week 48 and 96
(randomly to intake of vitamin D supplementation), and
frozen at −70 °C until batch analyses. 25(OH)D was
measured by spectroscopy detecting total concentrations
of both 25(OH)D2 and 25(OH)D3 at the Hormone labora-
tory at Haukeland University Hospital. The coefficient of
variat4ion (CV) was 5.3% at 20 nmol/L and 4.0% at 239
nmol/L 25(OH)D. PINP and CTX1 were measured by
electrochemiluminiscence at the Hormone laboratory at
Oslo University Hospital. The CVs were 11% for PINP and
12% for CTX1, and the detection limits were 5–1200 μg/l
and 0,07–6,00 μg/l respectively.
The associations between bone markers and BMD at
baseline, and whether the concentrations of PINP and
CTX1 at baseline predicted BMD change from baseline
to week 96, were analyzed with linear regression. The
longitudinal changes in CTX1, PINP and PTH were
modelled with two separate linear mixed models. The
models included time of measurement, treatment arm,
time-treatment interaction, and a random intercept for
each participant. The markers were log-transformed,
making the estimated differences interpretable as percent-
ages. The models formed the basis for all inferences on
the relationship between vitamin D and the markers. To
investigate whether disease modifying drugs could influ-
ence the results, we also used a model which included the
drug treatment status at each sample time.
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Results
Serum samples for measurement of bone markers were
available from 68 participants who completed the study.
Baseline characteristics of the study population are shown
in Table 1. As reported previously [28] there were no
group differences in age, body mass index (BMI), smoking,
use of disease modifying drugs, disability as measured by
EDSS, calcium intake or relapse rate the previous year.
The serum concentration of 25(OH)D increased to
123.2 ± 34.2 nmol/L at week 96 in the vitamin D group,
and to 61.8 ± 25.2 nmol/L in the placebo group. Ionized
calcium was similar and unchanged at baseline and week
96 in both groups (1.2 ± 0.0 nmol/L).
The concentrations of CTX1, PINP and PTH did not
differ significantly between the groups at baseline (Table 2).
The concentrations of CTX1 and PINP remained similar
between treatment groups throughout the study group,
whereas PTH was lower in the vitamin D group at both
week 48 and at week 96.
The associations between the bone markers and BMD
are presented in Table 3. There was a weak negative as-
sociation between CTX1 and PINP and hip BMD at
baseline, and between CTX1 and spine BMD at baseline
(p < 0.05). The baseline marker concentrations did not
predict change in BMD from baseline to week 48 or
week 96.
The effect of vitamin D supplementation was finally
analyzed using a linear mixed model for each bone
marker with random patient-wise intercepts. There was
no significant difference between treatment groups in
the change of CTX1, PINP or PTH from baseline to
week 48 or from baseline to week 96 (Table 4). These re-
sults did not change substantially when immune modu-
latory treatment was included in the model (results not
shown). In total 14 patients received methylprednisolone
for MS attack. Of these two in the placebo and two in
the vitamin D groups were treated during the last 6
months prior to the first blood sampling, and three in
the vitamin D group and one in the placebo group dur-
ing the last 6 months prior to the last blood sampling.
Excluding the 14 patients treated with methylpredniso-
lone did not alter the results (data nor shown).
Discussion
To our knowledge the effect on vitamin D supplementa-
tion on markers of bone formation and resorption in per-
sons with MS has not been reported previously. We found
that increasing mean 25(OH)D levels from 56 to 123
nmol/L with weekly high dose vitamin D supplementation
did not influence biochemical markers of bone formation
or turnover in persons with MS receiving calcium supple-
mentation. This concurs with the previously negative
Table 1 Baseline characteristics
Vitamin D group (N = 35) Placebo group (N = 33)
Females N (%) 24 (69) 24 (73)
Age (years) Mean (range) 40 (21–50) 41 (26–50)
Body mass index Mean (range) 25.9 (21.0–40.7) 26.4 (18.4–39.9)
Ongoing smoking N (%) 15 (43) 14 (42)
EDSS Median (range) 2.5 (0–4.5) 2.0 (0–4.5)
Annualised relapse rate Mean (range) 0.11 (0–0.54) 0.15 (0–1.10)
Immunomodulatory treatment N (%) 17 (49)a 17 (52)b
Serum 25(OH)D (nmol/L) Mean (SD) 55.6 (29.0) 57.3 (21.8)
Hip BMD (mg/cm2) Mean (SD) 1018.8 (98.8) 968.9 (119.9)
Spine BMD (mg/cm2) Mean (SD) 1205.2 (117.7) 1165.7 (135.6)
Distal radius BMD (mg/cm2) Mean (SD) 484.8 (67.1) 472.8 (80.6)
a16 patients on IFN-β and one on glatiramer acetate
b15 patients on IFN-β, one on glatiramer acetate and one on natalizumab
Table 2 Bone markers and PTH throughot the study period
CTX1 (μg/l) PINP (μg/l) PTH pmol/L
Placebo Vitamin D p-value* Placebo Vitamin D p-value* Placebo Vitamin D p-value*
Baseline. mean (SD) 0.20 (0.10) 0.22 (0.11) 0.59 43.10 (15.1) 40.32 (10.0) 0.57 4.75 (1.08) 4.68 (1.29) 0.66
Week 48. mean (SD) 0.22 (0.16) 0.21 (0.11) 0.79 43.36 (17.2) 38.56 (10.6) 0.43 3.68 (1.04) 3.13 (0.96) 0.017
Week 96. mean (SD) 0.23 (0.17) 0.23 (0.12) 0.98 42.54 (15.0) 43.52 (10.6) 0.22 3.96 (1.27) 3.39 (1.00) 0.046
*Obtained from linear mixed model
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results on BMD in the same cohort [21], and also with
data obtained in healthy persons [29]. Moreover, we here
showed that neither CTX1 nor PINP at baseline predicted
BMD loss the subsequent 96 weeks. This is in contrast
with a previous study comprising 29 MS patients followed
for 3.1 ± 1.9 years, reporting a decline in BMD in the hip
but not in the lumbal spine correlated inversely with bone
turnover markers [30]. Whereas the patients included in
these studies were fairly comparable regarding disease
duration, BMI and disability levels, all known to be im-
portant for bone health in MS, only 50% of our patients
received immunomodulatory treatment compared to
100% in the previous study [30]. Immunomodulatory
drugs, including interferon beta which was most com-
monly used by our patients, could affect bone loss [31].
The use of immunomodulatory treatment did however
not influence the effect of vitamin D on bone markers,
and was not associated with BMD at baseline in our pa-
tients [32]. Other possible explanations for this discrep-
ancy include differences in sample sizes and duration of
follow up.
The vitamin D measurements in this study were per-
formed in January and February and should therefore
represent the seasonal nadir fairly well [33]. At this time
point 18 of 35 patients in the treatment group had
25(OH)D levels above 50 nmol/L, which are considered
adequate for maintenance of good bone health by the
Institute of Medicine. Clear evidence of vitamin D defi-
ciency (25(OH)D below 25 nmol) were only recorded in
nine patients in each treatment group. It is conceivable
that people with vitamin deficiency have a better effect
of vitamin D supplementation on bone health than
people with adequate vitamin D status, and that the low
proportion of patients with vitamin D deficiency contrib-
uted to the negative results.
RCTs of vitamin D supplementation have not shown a
consistent effect on BMD or fracture risk in the general
population [17]. This does not exclude that particular
subgroups with increased risk of osteoporosis due to
immobilization, inadequate nutrition, medication or dis-
ease may need vitamin D supplementation to maintain
bone health [8]. Our study population had rather low dis-
ease activity and their ambulation was only moderately
impaired. MS patients with more advanced disability are
more prone to both accelerated bone loss and vitamin D
deficiency D [34], and could benefit more from vitamin D
supplementation than those included in this study.
There are several strengths and limitations of this
study. The randomized design minimized the risk of selec-
tion bias, and rigorous follow-up throughout the study
period ensured adherence to the study medication. The
optimal 25(OH)D level for bone health is not known, but
the dose used in this trial was well above 800 IU per day
which has been suggested to prevent fracture in meta-
analysis [35], and brought 25(OH)D in most patients
above 75–100 nmol/L which has been suggested by sev-
eral experts to be adequate [19, 36]. The main weakness
of the study is the limited size, which was not sufficient to
perform subgroup analyses or to detect minor yet relevant
effects of vitamin D supplementation. Moreover, patients
were allowed to continue use of vitamin D supplements,
and more than 50% of the patients in the placebo group
reported a vitamin D intake exceeding 7.5 μg/day. This
concurs with the generally favorable vitamin D status of
our patients. It is conceivable that depriving the patients
from their vitamin D supplements could have increased
the chance for a positive result, but it would expose pa-
tients in the placebo group to the risks of vitamin D defi-
ciency, and would be particularly problematic in a
population living north of the Arctic Circle. Another po-
tential weakness is the use of weekly dosing of vitamin
D3. Although weekly dosing leads to a stable serum con-
centration of 25(OH)D, which has a long half- life, the ef-
fect on other vitamin D metabolites is different. Notably,
the serum concentration of native vitamin D, which likely
plays an important role as substrate for synthesis of active
1,25-dihydroxyvitamin D in several tissues, peaks after six
to 8 h and thereafter falls rapidly [37]. It is therefore
Table 3 Association between bone markers at baseline and
BMD (regression coefficients)
BMD CTX1 PINP
Baseline hip −279.4* −2.42*
Baseline spine −385.0* −2.12
Baseline distal radius 91.3 1.05
DELTA hip −7.6 0.10
DELTA spine 61.5 0.40
DELTA distal radius −30.9 0.30
*p < 0.05; DELTA indicated the difference in BMD from baseline to week 96
Table 4 Effect of high dose vitamin D supplementation compared to placebo on bone markers
Week 48 Week 96
Change from baseline, percent difference (95% CI) p-value* Change from baseline, percent difference (95%CI) p-value*
PINP -5.10% (−17.77, 7.56) 0.43 10.26% (−2.48 22.99) 0.12
CTX1 -6.68% (−33.62, 20.25) 0.63 −3.60% (−30.67, 23.48) 0.80
PTH -13.69% (−29.55, 2.12) 0.09 −10.9% (−26.81, 5.03) 0.17
*Obtained from linear mixed model
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possible that daily supplementation is better than weekly
supplementation of vitamin D.
Conclusions
Our results do not support that high dose weekly vita-
min D supplementation is beneficial for bone health in
ambulatory persons with MS, and suggest that weekly
vitamin D supplementation alone is not sufficient to pre-
vent bone loss in persons with MS who are not vitamin
D deficient.
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